Press Releases

Date Title and Summary Additional Formats
Toggle Summary Flexion Therapeutics Announces Exercise of Underwriters' Over-Allotment Option and Closing of Public Offering of Common Stock View HTML
Toggle Summary Flexion Therapeutics Announces Pricing of Public Offering of Common Stock View HTML
Toggle Summary Flexion Therapeutics Announces Public Offering of Common Stock View HTML
Toggle Summary Flexion Therapeutics Announces That FDA Has Removed Clinical Hold on FX006 View HTML
Toggle Summary Flexion Therapeutics to Present at Stifel Healthcare Conference 2014 View HTML
Toggle Summary Flexion Therapeutics Reports Third-Quarter 2014 Financial Results View HTML
Toggle Summary Flexion Therapeutics to Report Third-Quarter 2014 Financial Results View HTML
Toggle Summary Flexion Therapeutics Announces Clinical Hold of FX006 Phase 2b Clinical Trial in Osteoarthritis of the Knee View HTML
Toggle Summary Flexion Therapeutics Announces Issuance of U.S. Composition of Matter Patent for Lead Candidate FX006
Patent Underpins FX006 Formulation Technology and Provides Intellectual Property Protection Into 2031
View HTML
Toggle Summary Flexion Therapeutics to Start FX006 Phase 3 Pivotal Trial in 2014; Following FDA Meeting, Development Plan Advanced by One Year View HTML